Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) has announced that Ascendis Pharma Bone Diseases A/S, a wholly owned subsidiary of Ascendis Pharma A/S, has entered into a US$150 million capped synthetic royalty funding agreement with Royalty Pharma based on US net sales of YORVIPATH. Under the terms of the agreement, Ascendis receives an upfront payment of US$150 million in exchange for a 3% royalty on US net sales of YORVIPATH. The royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x, or 1.65x if Royalty Pharma receives royalties in that amount by December 31, 2029.
Latham & Watkins LLP represents Ascendis in the transaction with a transactional team led by partners Dan Van Fleet, Mark Roeder, John Williams, and Haim Zaltzman, with associates Erin Cusenbary, Tyler Israel, and Ryleigh Chen; on intellectual property matters by partner Jekkie Kim, with associates Mizuna Sekine and Patrick Chew; on tax matters by partner Eric Cho, with associate Sam Yang; and on FDA regulatory matters by partner Ben Haas and counsel Monica Groat.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
